@article{3120368,
    title = "MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period",
    author = "Kanni, T. and Argyropoulou, M. and Dinarello, C.A. and Simard, J. and Giamarellos-Bourboulis, E.J.",
    journal = "CLINICAL AND EXPERIMENTAL DERMATOLOGY",
    year = "2021",
    volume = "46",
    number = "1",
    pages = "162-163",
    publisher = "Wiley-Blackwell Publishing Ltd",
    doi = "10.1111/ced.14333",
    keywords = "adalimumab;  bermekimab;  interleukin 1alpha;  placebo;  adalimumab;  IL1A protein, human;  interleukin 1alpha;  MABp1 monoclonal antibody;  monoclonal antibody, clinical article;  controlled study;  disease exacerbation;  double blind procedure;  drug efficacy;  drug targeting;  follow up;  human;  Letter;  open study;  patient-reported outcome;  phase 2 clinical trial;  priority journal;  randomized controlled trial;  suppurative hidradenitis;  chemistry;  drug tolerance;  intravenous drug administration;  metabolism;  organization and management;  phase 2 clinical trial (topic);  randomized controlled trial (topic);  safety;  suppurative hidradenitis;  treatment outcome, Adalimumab;  Antibodies, Monoclonal;  Antibodies, Monoclonal, Humanized;  Clinical Trials, Phase II as Topic;  Drug Tolerance;  Eligibility Determination;  Hidradenitis Suppurativa;  Humans;  Infusions, Intravenous;  Interleukin-1alpha;  Patient Reported Outcome Measures;  Placebos;  Randomized Controlled Trials as Topic;  Safety;  Treatment Outcome"
}